NovoCure Ltd (NASDAQ: NVCR) kicked off on Friday, down -3.30% from the previous trading day, before settling in for the closing price of $11.51. Over the past 52 weeks, NVCR has traded in a range of $10.91-$34.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -83.87% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -1.22%. With a float of $99.04 million, this company’s outstanding shares have now reached $111.80 million.
In an organization with 1488 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 76.38%, operating margin of -27.42%, and the pretax margin is -22.54%.
NovoCure Ltd (NVCR) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Medical Devices Industry. The insider ownership of NovoCure Ltd is 11.41%, while institutional ownership is 77.95%. The most recent insider transaction that took place on Jul 29 ’25, was worth 231,800. In this transaction Chief Financial Officer of this company bought 20,000 shares at a rate of $11.59, taking the stock ownership to the 141,150 shares. Before that another transaction happened on Jun 03 ’25, when Company’s Director sold 999 for $17.28, making the entire transaction worth $17,259. This insider now owns 3,054 shares in total.
NovoCure Ltd (NVCR) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.28 earnings per share (EPS), higher than consensus estimate (set at -0.33) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.49 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1.22% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.18% during the next five years compared to -83.87% drop over the previous five years of trading.
NovoCure Ltd (NASDAQ: NVCR) Trading Performance Indicators
Take a look at NovoCure Ltd’s (NVCR) current performance indicators. Last quarter, stock had a quick ratio of 1.39. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.97.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.56, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.68 in one year’s time.
Technical Analysis of NovoCure Ltd (NVCR)
Let’s dig in a bit further. During the last 5-days, its volume was 2.13 million. That was better than the volume of 1.21 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 27.39%.
During the past 100 days, NovoCure Ltd’s (NVCR) raw stochastic average was set at 2.40%, which indicates a significant decrease from 3.80% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.87 in the past 14 days, which was higher than the 0.86 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.93, while its 200-day Moving Average is $19.95. However, in the short run, NovoCure Ltd’s stock first resistance to watch stands at $11.51. Second resistance stands at $11.88. The third major resistance level sits at $12.08. If the price goes on to break the first support level at $10.93, it is likely to go to the next support level at $10.73. The third support level lies at $10.36 if the price breaches the second support level.
NovoCure Ltd (NASDAQ: NVCR) Key Stats
The company with the Market Capitalisation of 1.24 billion has total of 111,799K Shares Outstanding. Its annual sales at the moment are 605,220 K in contrast with the sum of -168,630 K annual income. Company’s last quarter sales were recorded 158,810 K and last quarter income was -40,140 K.
